Business
Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.
FEATURED STORIES
A fresh FDA review for Biohaven’s embattled ataxia drug lifted the biotech’s shares, while a late-stage lung cancer miss battered ArriVent, which failed to rebound even after encouraging early ADC data.
Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.
Biogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO Chris Viehbacher said on a Q3 earnings call Wednesday.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.
Neurocrine Biosciences will conduct a new study for the rare disease drug Vykat to explore dosing and safety in patients with Prader-Willi syndrome who have complex health issues.
Novartis is discontinuing a neurodegeneration alliance with BioArctic in which the companies aimed to develop a drug candidate that could cross the blood-brain barrier.
Sales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.
Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.
The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.
In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the higher dose failed to deliver the same benefit.
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.
Saudi Arabia is building the regulatory framework, partnerships infrastructure and IP landscape needed to support a biotech ecosystem, despite regional political instability. Whether it can produce sustainable biotech companies and a resilient manufacturing base for global production remains an open question, but the future looks bright.